The estimated Net Worth of David P. Rosenbaum is at least $3.6 Million dollars as of 20 August 2024. David Rosenbaum owns over 7,219 units of Ardelyx Inc stock worth over $931,262 and over the last 10 years he sold ARDX stock worth over $1,854,813. In addition, he makes $812,658 as Chief Development Officer at Ardelyx Inc.
David has made over 44 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,219 units of ARDX stock worth $42,303 on 20 August 2024.
The largest trade he's ever made was selling 61,640 units of Ardelyx Inc stock on 6 June 2022 worth over $40,066. On average, David trades about 6,043 units every 57 days since 2015. As of 20 August 2024 he still owns at least 156,252 units of Ardelyx Inc stock.
You can see the complete history of David Rosenbaum stock trades at the bottom of the page.
Dr. David P. Rosenbaum, Ph.D. is Chief Development Officer of the Company. From 2003 to 2008, he was Vice President of Drug Development for Trine Pharmaceuticals, Inc., a biopharmaceutical company, where he was developing a novel non-systemic therapeutic for the treatment of IBS. In addition, Dr. Rosenbaum previously served as Vice President of Preclinical Research and Development at GelTex Pharmaceuticals, a biopharmaceutical company, where he was responsible for the preclinical development of Renagel and Welchol. He received a B.A. in Biology from the University of Pennsylvania, a M.S. in Toxicology from Albany Medical College and a Ph.D. in Pharmacology from Boston University School of Medicine.
As the Chief Development Officer of Ardelyx Inc, the total compensation of David Rosenbaum at Ardelyx Inc is $812,658. There are 2 executives at Ardelyx Inc getting paid more, with Michael Raab having the highest compensation of $1,728,920.
David Rosenbaum is 59, he's been the Chief Development Officer of Ardelyx Inc since 2017. There are 4 older and 15 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
David's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: